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Phosphorus 31 nuclear magnetic
resonance spectroscopy suggests a
mitochondrial defect in claudicating
skeletal muscle
Iraklis I. Pipinos, MD, Alexander D. Shepard, MD, Petros V.
Anagnostopoulos, MD, Asterios Katsamouris, MD, and Michael D. Boska,
PhD, Detroit, Mich, and Crete, Greece
Objective: Decreased oxygen supply is generally accepted as the primary cause of muscle
dysfunction in patients with peripheral arterial occlusive disease (PAOD) and intermittent
claudication, although reported morphologic changes in the mitochondria of claudicat-
ing muscle suggest that impaired energy utilization may also play a role. With the mea-
surement of the phosphate-rich compounds of muscle energy metabolism (adenosine-
triphosphate [ATP], adenosinediphosphate [ADP], and phosphocreatine [PCr]) and pH,
phosphorus P 31 magnetic resonance spectroscopy (31P MRS) provides a unique, nonin-
vasive method to investigate this hypothesis further.
Methods: Calf muscle bioenergetics were studied in 12 men with moderate claudication
(ankle-brachial index ≥0.5 and ≤0.8) and 14 normal control subjects with the use of 31P
MRS and standard treadmill testing. Phosphorus MRS evaluation of the superficial pos-
terior calf muscles was carried out with a 90-second submaximal isometric plantar flex-
ion exercise. This mild exercise was chosen to permit in-magnet testing and to allow
study of intrinsic mitochondrial efficiency under conditions of unchallenged blood flow.
Phosphocreatine and ADP recovery time constants (t.c.), two very sensitive measures of
oxidative mitochondrial function, as well as intracellular pH and ATP production via
anaerobic glycolysis were determined during three exercise sessions and the results aver-
aged and compared to known values obtained from a control population.
Results: During the 31P MRS protocol, the end exercise intracellular pH (7.11 ± 0.01 vs
7.11 ± 0.01) and ATP production by anaerobic glycolysis (0.13 ± 0.05 vs 0.14 ± 0.03
mmol/L per second) were no different in PAOD patients versus control subjects, con-
firming that the protocol exercise did not significantly reduce oxygen supply.
Phosphocreatine and ADP recovery t.c. (137 ± 41 vs 44 ± 3 seconds and 60 ± 10 vs 29
± 2 seconds, respectively) were significantly slower than normal (P < .05, t test). There
was, however, no correlation between these measures of mitochondrial function and any
treadmill parameter (P > .5, Pearson moment correlation).
Conclusions: Phosphorus 31 MRS provides the first direct evidence of defective energy
metabolism in the mitochondria of claudicating calf muscle. This defect appears to be
independent of both arterial flow and the severity of occlusive disease in patients with
mild to moderate claudication. Coupled with documented ultrastructural and DNA
abnormalities in the mitochondria of claudicating skeletal muscle, these data provide evi-
dence for a secondary cause of muscle dysfunction in intermittent claudication. (J Vasc
Surg 2000;31:944-52.)
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Muscle bioenergetics in patients with peripheral
arterial occlusive disease (PAOD) has not been well
characterized. The primary cause of muscle dysfunc-
tion in claudication is presumed to be an imbalance
between oxygen supply and demand in the sympto-
matic limb.1 Arterial occlusive disease restricts the
normal increase in blood flow required by skeletal
muscle during exercise, inducing muscle ischemia
and resulting in symptoms of tightness, cramping,
and fatigue. There is, however, increasing evidence
that impaired energy utilization may also play a role
in the pathophysiology of PAOD. Morphologic
defects including hyperplasia, proliferation and bal-
looning of the cristae, and paracrystalline inclusions
have been well described in the mitochondria of
claudicating skeletal muscle.2-4 In addition, recent
studies have demonstrated extensive mitochondrial
DNA damage in muscle biopsies taken from claudi-
cants.5,6 These changes in the structure and genetic
fabric of mitochondria may result in defects in mito-
chondrial function and suggest the possibility of
impaired energy utilization as a secondary cause of
the muscle dysfunction of intermittent claudication.
Recent advances in nuclear magnetic resonance
spectroscopy have made it possible to investigate
muscle bioenergetics in vivo and noninvasively.7,8
With the measurement of the concentrations of
adenosinetriphosphate (ATP), adenosinediphos-
phate (ADP), phosphocreatine (PCr), and intracel-
lular pH with a time resolution of 1 second before,
during, and after exercise, 31P MRS can determine
the rate at which phosphoenergetic reactions
occur.8-10 As the central organelles in cellular energy
metabolism, mitochondria are the primary focus of
most kinetically resolved 31P MRS exercise studies.
We therefore decided to use 31P MRS to study mito-
chondrial function in patients with claudication. Our
hypothesis was that there is a primary mitochondri-
al defect in claudicating skeletal muscle.
The energy state of muscle is the result of a bal-
ance between ATP production and utilization. ATP
is an energy-rich compound that provides the ener-
gy for muscle contraction by dephosphorylation into
ADP and inorganic phosphate (Pi):
ATP      ADP + Pi + Energy
During exercise three separate energy pathways
blend and with significant overlap provide uninter-
rupted ATP production. When exercise begins, the
most important source of ATP resynthesis is provid-
ed by PCr breakdown through the creatine kinase
(CK) pathway also known as the “immediate” ATP-
generating system:
PCr + ADP + H+ Cr + ATP
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Within seconds after the initiation of exercise an
increasingly greater proportion of ATP synthesis 
is generated by anaerobic glycolysis (AnGly).
Glycolysis is the “short-term” ATP-generating sys-
tem of the cell:
Glucose + 2ADP + 2Pi → 2 Lactate + 2 ATP 
+ 2 H2O + 2 H+
This pathway contributes most of the ATP
requirements of the muscle in the first few minutes
of exercise, until the “long-term” pathway of oxida-
tive phosphorylation (OxPhos) is incrementally acti-
vated, becoming the dominant ATP provider for the
duration of exercise:
3 ADP + 3 Pi + NADH + 1⁄2 O2 + H+ NAD+
+ 3 ATP + H2O
With the cessation of exercise, both the CK and
AnGly pathways are immediately deactivated.
Phosphocreatine levels are then restored via the CK
reaction, utilizing ATP produced solely through
OxPhos. Similarly, ADP levels that had increased
during exercise by dephosphorylation of ATP return
back to their low resting levels as OxPhos converts
ADP to ATP. Oxidative phosphorylation occurs
exclusively in mitochondria, and therefore postexer-
cise PCr and ADP recovery rates are good measures
of mitochondrial function.7,8
METHODS
This trial was conducted on an outpatient basis at
the Henry Ford Hospital, a tertiary care, referral
medical center. Twelve patients with mild to moder-
ate intermittent claudication resulting from PAOD
Fig 1. 31P spectrum collected from the calf muscle of a
patient with moderate claudication.
and 14 moderately active control subjects were
recruited. All claudicants were men and nondiabetic
with an ankle brachial index (ABI) of 0.8 or below,
but not below 0.5. This protocol was approved by
our institutional review board, and informed con-
sent was obtained from all participating patients.
31P MRS measurements
Calf muscle bioenergetics were measured at rest
and during and after 90-second isometric submaxi-
mal plantar flexion exercise. All PAOD patients
underwent 31P MRS evaluations of the calf muscles
in the extremity with the lower ABI. All normal con-
trol subjects had evaluations of the calf muscles in
their right lower extremity. Subjects fasted and
abstained from caffeine for 6 hours before being
studied.
31P MRS exercise. The main part of the MRS
instrument is a 3 Tesla whole-body magnetic reso-
nance imaging and spectroscopy system (Magnex
Scientific Ltd, Abington, UK) utilizing an imaging
console (Surrey Medical Imaging Systems, Surrey,
UK). The 31P MRS protocols used in these series have
been previously described in detail.9,10 In brief, the
extremity to be studied is positioned in a laboratory-
built exercise device. The apparatus consists of an in-
line isometric ergometer, with a force transducer/ana-
lyzer (Tedea #1250, 300 kg; Tedea Huntleigh, Inc,
Canoga Park, Calif) and a 9-cm inductively coupled
surface coil. The coil is tuned to the resonance fre-
quency of phosphorus atoms (51.7 MHz at 3.0
Tesla). The leg is positioned in the device in extension
at the level of the knee joint, and the coil is snugly
strapped over the posterior calf musculature. The sub-
ject’s foot is secured to the pedal of the in-line
ergometer. Subjects push against the pedal to isomet-
rically exercise their posterior compartment muscles
(foot flexors). A standard proton-based magnetic res-
onance 5-slice image of the calf is first obtained, and
the maximum cross-sectional area of the gastrocne-
mius/soleus muscle group is measured to calculate
the theoretical force generating capacity of the muscle
group.11 The subject then plantar flexes his foot to a
target force of approximately 60% ± 15% (mean ± SD)
of the estimated maximum capacity of his calf mus-
cles. These calculations are based on previous studies
performed on normal subjects.10 While in the magnet
the subject performs three isometric plantar flexion
exercises. Each in-magnet exercise lasts 90 seconds,
and the patient rests for 15 minutes between exercis-
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Fig 2. Stacked plot of 31P MRS spectra obtained from the calf muscle of a patient with moderate clau-
dication. The original data set consisted of 400 spectra collected with 1-second time resolution during
a single exercise. For clarity, groups of approximately 10 spectra were summed and displayed as a sin-
gle spectral curve in the figure. During exercise, muscle PCr levels drop and Pi increases, and then they
gradually return to baseline during recovery. The ATP levels remained unchanged during the exercise.
es. Phosphorus spectra are collected every 1 second,
before and during study exercise and throughout the
first 5 minutes after the exercise.
The short-duration isometric workout of the
foot flexors performed during 31P MRS was specifi-
cally chosen in contrast to the longer isotonic proto-
col of the entire leg used during treadmill evaluation
because (1) it enables in-magnet testing, (2) it iso-
lates work to a single muscle group, and (3) it is a
mild exercise that does not challenge the diseased
arterial inflow of PAOD patients enough to produce
exercise-induced muscle ischemia. Muscle bioener-
getics can thus be tested under conditions of normal
oxygen supply, which allows for direct study of
intrinsic mitochondrial efficiency.
Phosphorus MRS spectra analysis. Fig 1
depicts a typical in vivo 31P MRS spectrum of the
posterior calf musculature obtained at rest. The
phosphorus atom has an odd number of neutrons
and protons in its nucleus and is therefore detectable
with magnetic resonance techniques. Phosphorus is
the central element of phosphate, which in turn is an
essential component of many important biomole-
cules. The phosphorous nuclei of DNA, RNA, most
phospholipids, and phosphoproteins are immobile
and do not yield an easily measurable signal in a
magnetic field. ATP, ADP, Pi, and PCr are the prin-
cipal mobile phosphorus-rich compounds present in
sufficient concentrations in tissue to yield a sharp,
easily measurable phosphorus spectroscopic signal.
Each one of the three phosphate atoms of ATP have
different chemical shifts and clearly resolved peaks.
In the 31P MRS spectrum the most prominent peak
is PCr, which lies just to the left of γ-ATP. The spec-
tra of the two ADP phosphates cannot be seen
because their natural concentrations in the cell are
very low (50-1000 times lower than those of ATP)
and do not produce clearly resolved peaks. ADP
concentrations, however, can be readily calculated
from the pH and the measured concentrations of
ATP, PCr, and free creatine. The three smaller peaks
to the left of PCr are phosphodiesters (PDE), Pi,
and phosphomonoesters (PME). The Pi peak is of
particular importance because it represents the sum
of visible mono and dibasic inorganic phosphates.
These two phosphate species participate in the intra-
cellular phosphate buffer system and are in rapid
exchange, depending on the cellular pH. The chem-
ical shift of the Pi peak is the weighted mean of these
two species; changes in the pH alter the balance
between these two phosphate species and thus pro-
duce a change in the chemical shift of the Pi peak.
Acidosis shifts the peak closer and alkalosis shifts it
farther away from the PCr peak. These migrations of
the Pi peak in relation to the stable position of the
PCr peak can be used as a very sensitive in vivo mea-
sure of intracellular pH.12,13
Fig 2 depicts a series, or stackplot, of spectra
obtained during exercise in a patient with moderate
claudication. Phosphocreatine concentration drops
and Pi increases during exercise, and then these
quickly return to normal values during recovery.
ATP levels remain unchanged during the exercise.
Maintenance of stable ATP levels is of critical impor-
tance to normal cellular function; ATP concentra-
tions drop only under extreme circumstances (eg,
profound ischemia or direct cellular damage).
Important information regarding cellular energy
metabolism can be obtained from these spectra. By
using the bioenergetic stoichiometric equations, the
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Table I. Comparison of 31P MRS parameters in claudicants and controls 
Claudicants Controls P value
End-exercise values
PCr (mmol/L) 18.9 ± 1.3 17.4 ± 0.7 .3
Pi (mmol/L) 11.6 ± 1.1 11.3 ± 0.6 .8
ADP(µmol/L) 41 ± 6 42 ± 5 .9
pH 7.11 ± 0.01 7.11 ± 0.01 .9
Exercise metabolism values
An Gly (mmol/L/s) 0.14 ± 0.01 0.13 ± 0.01 .92
CK (mmol/L/s) 0.07 ± 0.01 0.06 ± 0.01 .6
Ox Phos (mmol/L/s) 0.12 ± 0.02 0.13 ± 0.01 .71
Mean % MVC 56 ± 3% 57 ± 3% .77
Recovery
PCr t.c. (s) 137 ± 41 44 ± 3 .02
Pi t.c. (s) 139 ± 42 44 ± 3 .02
ADP t.c. (s) 60 ± 10 29 ± 2 .002
All values are mean ± 1 SE.
% MVC, Percent maximum voluntary capacity of calf flexors maintained during exercise (calculated from muscle cross-sectional area).
relative contributions of the OxPhos, AnGly, and
CK pathways to ATP production during exercise can
be derived. Intracellular pH can be used as a marker
for the presence of anaerobic metabolism. Finally,
the functional status of the muscle cell mitochondria
can be determined by measuring the postexercise
recovery of PCr and ADP. The recovery rates of
these compounds are governed solely by mitochon-
drial OxPhos and constitute a sensitive measure of
mitochondrial efficiency.
Treadmill evaluation
Treadmill stress testing. Patients with PAOD
walked on an inclined (gradient, 12.5 degrees)
treadmill at a speed of 1.5 mph for a total of 5 min-
utes (or less if claudication forced them to stop).
Standard technique was used for the calculation of
ABIs. More specifically, brachial and ankle (dorsalis
pedis and posterior tibial arteries) systolic blood
pressures were measured with use of a suitably sized
blood-pressure cuff and a handheld, pencil-sized
continuous wave Doppler flow probe. For each
extremity the ratio of the higher of the two ankle
pressures over the higher of the two brachial pres-
sures was calculated as the baseline ABI. The same
pedal artery was used for calculation of the postex-
ercise ABIs. Treadmill stress testing produces maxi-
mum flow demands to the most symptomatic leg, its
parameters correlate well with calf blood flow mea-
surements, and it is a highly accurate and readily
available method for assessing the severity of
PAOD.14 Measured parameters included (1) base-
line ABIs (2) ABIs at 1 minute postexercise, (3)
maximum drop in the ABIs, and (4) time required
for the ABIs to return to baseline.
Walking distances. After completion of the ini-
tial treadmill test and a rest period of 30 minutes,
patients walked again on the treadmill, and this time
the initial claudication distance and the maximum
walking capacity were determined. Initial claudica-
tion distance is the distance the patient can walk
under the above standardized circumstances before
experiencing the onset of pain; maximum walking
capacity is the maximum distance walked before dis-
comfort forces the patient to stop.
Four selected patients also underwent ABI mea-
surements in the most affected limb before and at 1
minute after performance of a submaximal 90-sec-
ond plantar flexion exercise. The exercise consisted
of standing on the toes and raising the heels off the
ground for 90 seconds and was intended to simulate
the in-magnet exercise to see if this exercise changed
arterial flow.
Statistics
MRS parameters from control subjects and
patients with PAOD were compared by means of
a t test. Correlations between treadmill and MRS
data in the PAOD population were performed by
using the Pearson correlation. A P value less than
.05 was considered indicative of a significant dif-
ference. Results are expressed as means ± SE
unless otherwise stated. Sigmastat (SPSS, Inc,
Chicago, Ill) and Sigmaplot (Jandel) statistics




Exercise spectra. All PAOD patients and normal
control subjects completed the MRS exercise proto-
col without having any calf symptoms resembling
claudication pain. As expected, during exercise PCr
decreased and Pi and ADP increased, while ATP lev-
els remained stable. There was no significant differ-
ence in the relative change of any of these individual
phosphorus metabolites between the PAOD and
normal groups.
Table I displays the end exercise intracellular pH
in the PAOD group compared with the control sub-
jects. In the claudicants the end exercise muscle cell
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Table II. Correlation between treadmill stress testing parameters and functional 31P MRS mitochondrial
indices
Baseline ABI % ABI drop ABI at 1 minute ABI recovery time ICD MWC
PCr t.c. r = –0.114 r = –0.159 r = 0.131 r = 0.064 r = –0.121 r = –0.039
P = .725 P = .641 P = .691 P = .850 P = .708 P = .905
ADP t.c. r = –0.128 r = –0.309 r = 0.276 r = –0.268 r = –0.206 r = –0.012
P = .692 P = .355 P = .411 P = .426 P = .521 P = .969
% ABI, Maximum drop in the ABI; ABI at 1 minute, ABI at 1 minute postexercise; ABI recovery time, time required for the ABI to
return to baseline; ICD, initial claudication distance; MWC, maximum walking capacity.
pH remained in the normal range and was the same
as in normals (7.11 ± 0.01 vs 7.11 ± 0.01). A com-
parison between the activation pattern of anaerobic
pathways during exercise in claudicants and in the
control subjects is also presented in Table I.
Specifically, in the claudicating muscle ATP produc-
tion by AnGly remained in a normal range and was
essentially the same as in normal muscle (0.14 ±
0.01 vs 0.13 ± 0.01 mmol/L per second). The ATP
consumed during exercise in both PAOD and nor-
mal muscle was regenerated by using virtually the
same combination and ratios of the OxPhos, AnGly,
and CK pathways (Table I).
Recovery spectra. Phosphocreatine recovery
was significantly slower in claudicating muscle than
in normal muscle (137 ± 41 vs 44 ± 3 seconds). In
addition, ADP recovery was significantly slower in
claudicating muscle (60 ± 10 vs 29 ± 2 seconds).
Interestingly, however, not all PAOD patients
demonstrated such delayed PCr and ADP recovery.
Three of the 12 (25%) claudicants had mitochondr-
ial indices (PCr recovery t.c. of 39 ± 8 seconds and
an ADP recovery of 26 ± 7 seconds), that fell with-
in the normal limits. In this case, normal limits were
defined as the mean ± 2 SD of the corresponding
value in the control group (ie, for PCr t.c. = 22-66
seconds and for ADP t.c. = 17-41 seconds). The
only noticeable, although not statistically significant
(P > .05), difference between the group of claudi-
cants with “normal” mitochondrial function and the
group with “abnormal” function was the duration of
claudication symptoms. In the subgroup with nor-
mal mitochondrial parameters, claudication symp-
toms had been present an average of 1.3 ± 0.3 years;
in the subgroup with abnormal mitochondrial para-
meters symptoms had been present a mean of 4.4 ±
1.6 years.
Treadmill data
Treadmill evaluation was performed only on the
claudicants. Subjects at rest had an average ABI of
0.65 ± 0.03 (range, 0.5-0.8). The ABI at 1 minute
after exercise dropped to 0.3 ± 0.05, constituting a
maximum reduction of 56% ± 7%. Posttreadmill
ABIs required an average of 13 ± 3 minutes to
return to baseline. The initial claudication distance
was 98 ± 32 meters, and the maximum walking
capacity was 354 ± 64 meters. There was no correla-
tion between any of these treadmill parameters,
which primarily reflect the severity of the arterial
occlusive process and any of the 31P MRS parame-
ters, which primarily assess end organ metabolic
function (Table II). More specifically, individuals
with the worst treadmill parameters did not neces-
sarily have the worst 31P MRS indices of mitochon-
drial function.
For the four claudicants who performed the 90-
second plantar flexion exercise while standing on
their toes, the ABI of the tested extremity at rest
averaged 0.675 ± 0.05 (range, 0.6-0.8), and at 1
minute postexercise changed insignificantly, to 0.65
± 0.1 (P > .05).
DISCUSSION
Intermittent claudication is a debilitating condi-
tion affecting more than 4 million people in the
United States.15-17 Although the main cause of clau-
dication is insufficient oxygen supply resulting from
arterial occlusive disease, the pathobiology of the
muscle dysfunction in claudication cannot be fully
explained on the basis of reduced blood flow alone.
Several studies have shown that measurements of
calf blood flow and ABIs do not correlate with
treadmill walking distances and that revasculariza-
tion of a diseased arterial segment does not neces-
sarily normalize exercise performance.18-20 It seems
likely that other factors contribute to the muscle
dysfunction seen in PAOD. Mitochondrial morpho-
logic defects have been well described in pathologic
studies of claudicating muscle.2-4 In addition, recent
studies have demonstrated extensive damage in the
mitochondrial DNA of skeletal muscle biopsy speci-
mens taken from claudicants.5,6 These changes in
the structure and genetic content of mitochondria
suggest the possibility that impaired energy metabo-
lism may play a role in claudication.
The objective of this study was to test the
hypothesis that there is a functional defect in these
abnormal claudicating mitochondria. A protocol was
designed to test skeletal muscle bioenergetics under
conditions of minimally perturbed blood flow,
which would allow for direct study of mitochondri-
al function without the confounding effects of
ischemia. We employed MRS methodology and
designed a specific exercise that enables in-magnet
testing at a level mild enough that muscle oxygen
demand does not appear to exceed oxygen supply. A
number of modifications were used to produce a
much more complete and accurate picture of muscle
biochemical function.21-28 These included (1) an in-
magnet exercise bench that isolates work to a single
muscle group, (2) total ergometric standardization
of exercise protocols, (3) use of an isometric exercise
to minimize motion artifacts, (4) testing only non-
diabetic persons, to exclude possible interference of
abnormal glucose metabolism with measurements of
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muscle energy states, and (5) performance of high
temporal resolution studies.
Exercise spectra showed that the ATP consumed
during exercise in both claudicating and normal
muscle was generated through activation of the same
combination of OxPhos, AnGly, and CK pathways.
No additional activation of anaerobic pathways was
observed in the PAOD patients compared with the
control subjects. At the end of the exercise, the
intracellular pH and the concentrations of ATP,
ADP, PCr, and Pi were no different in healthy versus
claudicating muscle. These results strongly suggest
that the 31P MRS exercise used did not significantly
reduce the oxygen supply to the exercising muscles
in the PAOD group. The minimal drop in the ABIs
of the 4 patients tested after the performance of the
90-second plantar flexion exercise further supports
our conclusion that the short, submaximal isometric
exercise did not demand more blood flow than can
be supplied by the diseased arterial circulation in
patients with mild to moderate claudication. Both
normal and PAOD subjects had comparable ATP
generation and utilization during exercise. All sub-
jects therefore began the exercise recovery phase
having similar energy debt to replenish through
mitochondrial OxPhos.
During the recovery phase, PCr and ADP recov-
ery time constants were significantly slower in the
PAOD group than in the normal subjects. Since the
exercise protocol did not appear to significantly
stress arterial inflow/oxygen supply to the exercising
muscle, this difference is likely the result of altered
mitochondrial function. These data strongly suggest
that the mitochondria in claudicating muscle do not
function normally.
The fact that 25% of the claudicants demonstrat-
ed “normal” mitochondrial function indices sug-
gests that the etiology of this defect is multifactorial
and cannot be attributed solely to the presence of
occlusive disease in the arterial tree supplying the
tested extremity. A combination of factors related to
the overall magnitude of the “ischemic insult” to
which the claudicating muscle is exposed may be
producing these defective mitochondria. Possible
factors include the location (eg, aortoiliac vs infrain-
guinal) of the occlusive process; the duration of
claudication symptoms; subjects’ normal exercise
levels; the presence, severity, and duration of associ-
ated comorbidities (eg, smoking, diabetes, hyper-
tension, dyslipidemias, congestive heart failure); and
even the subjects’ underlying nutritional status.
When we analyzed the characteristics of these
patients, the only noticeable difference identified
was a shorter duration of claudication symptoms in
the subgroup of claudicants with “normal” mito-
chondrial function. This finding, although not sta-
tistically significant, may indicate a possible cumula-
tive insult to mitochondrial function in claudicating
muscle resulting from repetitive episodes of
ischemia/reperfusion as encountered during routine
walking. Furthermore, the fact that severity of the
arterial occlusive process does not necessarily equate
with the gravity of the ischemic insult it produces
may be the reason why the postexercise treadmill
parameters did not correlate with the 31P MRS
indices. Treadmill stress testing, while being a very
accurate method for quantifying the severity of
occlusive disease,14 does not address any other com-
ponents related to the overall magnitude of the
“ischemic insult” produced by the occlusive lesions
it quantifies.
Previous investigations of claudicating muscle that
have used 31P MRS have suggested significantly pro-
longed recovery rates for PCr and ADP.21-28 In most
of these studies, patients were exercised to muscle
exhaustion with isotonic exercise protocols that intro-
duce exercise-induced muscle ischemia as a significant
confounding variable. Under such circumstances,
investigators did not attempt to extract specific con-
clusions about mitochondrial function. The work of
Zatina et al,21 however, is an interesting exception.
They performed 31P MRS on claudicants before, 
and soon after, lower extremity revascularization.
Although postoperatively the hemodynamics of the
limb were immediately restored to normal, there was
no corresponding improvement in the measured 31P
MRS indices of oxidative function.21 Based on these
findings, Zatina’s group concluded that “there is an
inadequacy of oxidative metabolism in the limb after
revascularization that is not secondary to ischemia.” At
that time, there was uncertainty about the exact mean-
ing of the discrepancy, but based on our current find-
ings it seems clear that this “inadequacy” is probably
the result of a primary mitochondrial defect in claudi-
cating skeletal muscle. This defect can be unmasked
when “claudicating” mitochondria are studied under
conditions of either a very mild exercise, such as in this
study, or soon after revascularization, as in Zatina’s
work.21 Under either circumstance, mitochondrial
function can be measured in a state of minimally per-
turbed blood flow. Zatina’s results also suggest that
this mitochondrial defect is not rapidly reversible with
revascularization
Findings from other laboratories suggest that
skeletal muscle in extremities of patients with PAOD
undergoes significant morphologic and metabolic
JOURNAL OF VASCULAR SURGERY
950 Pipinos et al May 2000
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 5 Pipinos et al 951
alterations. Mitochondrial ultrastructure is abnormal,
DNA and enzyme expression is altered, intermediates
of oxidative metabolism accumulate, and enzyme
activity may not increase normally in response to exer-
cise stimulation.2-6,29-34 These results, combined with
our findings, strongly suggest an intrinsic mitochon-
drial defect in claudicating muscle that is very similar
to those seen in mitochondrial myopathies.7,34
The significance of this defect is not entirely clear
at this point, but it seems likely that mitochondrial
dysfunction is at least a contributing factor to the
abnormal muscle physiology seen in claudication.
This reduction in metabolic efficiency may also be
responsible for the inadequacy of revascularization
to completely reverse exercise performance in
patients with PAOD.20,21 Additionally, amelioration
of this defect may be the reason why exercise reha-
bilitation and certain medications, like pentoxi-
fylline, cilostazol, and carnitines, improve the walk-
ing performance of claudicants without modifying
large vessel hemodynamics.35-37
This study represents an initial attempt to inves-
tigate mitochondrial function in claudicating skeletal
muscle, while minimizing the confounding effects of
reduced oxygen supply. Our data strongly suggest
the presence of an intrinsic mitochondrial defect that
results in impaired oxidative metabolism in patients
with mild to moderate claudication. Studies are cur-
rently underway in our laboratory to assess the
degree to which this defect is reversible with exercise
training, pharmacologic therapy, and revasculariza-
tion. Information from these studies will be impor-
tant to defining the true nature of this defect and its
contribution to the pathophysiology of intermittent
claudication.
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